Technology | Patient Positioning Radiation Therapy | September 04, 2019

Apollo MR3T Laser Receives FDA 510(k) Clearance

High-precision room laser used for patient positioning in radiation therapy in an electromagnetic environment

Apollo MR3T Laser Receives FDA 510(k) Clearance

September 4, 2019 — LAP LLC announced its Apollo MR3T positioning laser for radiation therapy has received U.S. Food and Drug Administration (FDA) 510(k) approval. The magnetic resonance (MR)-compatible room laser is currently the only product of its class approved the FDA, according to the company.

Apollo MR3T are high-precision room lasers for patient positioning in an electromagnetic environment. They are used in classical radiation therapy for patient positioning during imaging with a magnetic resonance tomograph (MRT) and in MR-guided radiation therapy with MR-LINAC (linear accelerators). During regular quality assurance (QA), test phantoms such as the newly developed Thales 3-D MR scanner, are placed quickly and easily with the help of certified lasers.

The components of the Apollo MR3T have minimal ferromagnetic properties and have no influence on the imaging. They are magnetically safe and optimally adapted to magnetic field strengths up to 3 Tesla. 

The device is available as a single laser or as a customized laser bridge to meet the requirements of any room situation. 

A high-quality aluminum housing protects the fine mechanics and optical components inside the Apollo MR3T. Break-resistant glass withstands all the stresses and strains of everyday clinical life. Even at a distance of 4 meters, the maximum width of the laser line is 1 mm. The line straightness within the line shows only submillimeter deviations even at a distance of 3 meters. The adjustment of the lasers is conveniently controlled via remote control. The fast and stepless adjustment of laser position and focus saves time for QA tasks and irradiation.

For more information:

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit